A closely connected, diverse and resilient pharmaceutical supply chain based in the United States and in U.S. allied countries (for example, Canada, Europe, India, Israel and Jordan) is the best means to ensure that U.S. patients and the U.S. health care system have access to a secure and consistent supply of critical pharmaceuticals. The United States already plays an important role in this supply chain, with generic companies providing for more than 52,000 jobs at nearly 150 facilities, and manufacturing more than 60 billion doses of prescription medicines annually.1
With strategic support from the U.S. government, the economic footprint of the generic drug industry in the U.S. can expand even more, leading to increased national security, a reduction of dependence on any one country for key pharmaceuticals or their components, and an expanded employment base.
1. Based on a 2016 survey of Association for Accessible Medicines’ member companies.